Dermatology

In this letter to the editor, investigators highlight the issues faced by patients with alopecia areata and the common barriers to JAK inhibitor access.

These data point to the necessity of incorporating disease burden in patient interactions and decision making for those under the age of 18 years.

These phase 2a data on IMG-007, a nondepleting anti-OX40 monoclonal antibody, highlight its efficacy among those with alopecia areata.

In this analysis, investigators compared older and younger patients with psoriasis in terms of drug survival and other results of biologic medications.

These data highlight the risk level among certain patients with psoriasis of excessive sun exposure, associated commonly with tanning.

The program can indicate the severity of nail psoriasis and allow practitioners to quickly and accurately diagnose patients.

In new preference research, the average participant with AA was willing to trade approximately 5 years of life to avoid impacts associated with 50–100% scalp hair loss.

In these findings, the FamilyPso tool was validated for assessing psoriasis burdens on family members in multiple countries.

Healthier hair and scalp according to Hair & Scalp CARE questionnaire responses was linked to lower levels of perceived stress and good sleep health.

An observational study has indicated a correlation between biologic medications and a lower risk of CVD: more research is needed to determine causality.

The findings may facilitate accurate diagnoses, which could help patients slow or stop permanent hair loss.

In this interview, Chovatiya and Shahriari highlight notable elements of the upcoming Revolutionizing Atopic Dermatitis (RAD) Conference.

Findings suggest BMI and education levels could be clinically relevant modifiable mediators of psoriasis risk attributable to reproductive factors.

This study highlights the different sex-related disparities as well as those among older adults with atopic dermatitis.

This SOCS News Update was filmed on-site at the 2025 AAD meeting, highlighting Nambudiri’s work and the launch of the AAD Clinical Image Collection.

These real-world findings on upadacitinib for atopic dermatitis highlight the drug’s efficacy and survival data among Australian patients.

This analysis suggests that exposures prior to, during, and following migration, along with structural factors are linked to skin health outcomes in migrant populations.

Without estrogen, the skin barrier weakens, leading to more severe and symptomatic psoriasis.

This analysis pointed to increased costs of biologics given the initiation of newer IL-17 and IL-23 inhibitors, suggesting the use of lower-cost options.

Dupilumab's approval marks the first new, targeted therapy for CSU in more than a decade and is the 7th indication for a disease with underlying type 2 inflammation.

Jennifer Soung, MD, joins The Medical Sisterhood to discuss her journey to launching LEADderm and how owning the podium has changed her career.

These findings highlight the impact of guselkumab on liver fibrosis progression among individuals living with psoriasis.

Revolutionizing Atopic Dermatitis 2025 Annual Meeting cochair Raj Chovatiya, MD, PhD, previews the upcoming meeting.

Mona Shahriari, MD, previews the upcoming Revolutionizing Atopic Dermatitis Annual Meeting being held in Nashville, TN from June 06-07.

A pair of experts discuss unmet needs and educational gaps related to atopic dermatitis.